Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma

Haematologica. 2015 Nov;100(11):e454-7. doi: 10.3324/haematol.2015.131144. Epub 2015 Aug 6.

Authors

Nathan H Fowler¹, Loretta J Nastoupil², Frederick B Hagemeister², Sattva S Neelapu², Luis E Fayad², Denise LeBlanc², Felipe Samaniego², Chan Yoon Cheah²

Affiliations

¹ Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Houston, TX, USA nfowler@mdanderson.org.
² Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Houston, TX, USA.

No abstract available

Keywords: lenalidomide; non-Hodgkin lymphoma; rash; rituximab.

Publication types

Clinical Trial, Phase II
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Exanthema / chemically induced*
Exanthema / pathology
Exanthema / therapy*
Female
Humans
Lenalidomide
Lymphoma, Non-Hodgkin / drug therapy*
Lymphoma, Non-Hodgkin / pathology
Male
Prospective Studies
Rituximab / administration & dosage
Rituximab / adverse effects
Thalidomide / administration & dosage
Thalidomide / adverse effects
Thalidomide / analogs & derivatives

Substances

Rituximab
Thalidomide
Lenalidomide

Associated data

ClinicalTrials.gov/NCT00695786